DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwan Mook Kim | - |
dc.contributor.author | S H Hong | - |
dc.contributor.author | M S Kim | - |
dc.contributor.author | Chang Woo Lee | - |
dc.contributor.author | Jong Soon Kang | - |
dc.contributor.author | Kiho Lee | - |
dc.contributor.author | Song Kyu Park | - |
dc.contributor.author | J W Han | - |
dc.contributor.author | H Y Lee | - |
dc.contributor.author | Y Choi | - |
dc.contributor.author | H J Kwon | - |
dc.contributor.author | G Han | - |
dc.date.accessioned | 2017-04-19T09:08:22Z | - |
dc.date.available | 2017-04-19T09:08:22Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | 10.1016/j.bmcl.2007.09.034 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/8140 | - |
dc.description.abstract | Novel δ-lactam-based HDAC inhibitors which have various substituted benzyl, bi-aromatic cap groups were prepared using ring closure metathesis reaction, and evaluated their HDAC inhibitory activities and anti-proliferative effects. Among prepared analogues, 11m and 11o have very strong HDAC enzymatic inhibition and showed the most potent growth inhibitory activity to five human tumor cell lines including PC-3, ACHN, NUGC-3, HCT-15, and MBA-MB-231 tumor cell lines. Compounds 11m and 11o also showed good tumor growth inhibition of MDA-MB-231 cells in in vivo xenograft model. Structure-activity relationship study using docking model explained the significance of hydrophobic aromatic cap groups for their in vitro activities. | - |
dc.publisher | Elsevier | - |
dc.title | Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors | - |
dc.title.alternative | Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors | - |
dc.type | Article | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.number | 22 | - |
dc.citation.endPage | 6238 | - |
dc.citation.startPage | 6234 | - |
dc.citation.volume | 17 | - |
dc.contributor.affiliatedAuthor | Hwan Mook Kim | - |
dc.contributor.affiliatedAuthor | Chang Woo Lee | - |
dc.contributor.affiliatedAuthor | Jong Soon Kang | - |
dc.contributor.affiliatedAuthor | Kiho Lee | - |
dc.contributor.affiliatedAuthor | Song Kyu Park | - |
dc.contributor.alternativeName | 김환묵 | - |
dc.contributor.alternativeName | 홍성희 | - |
dc.contributor.alternativeName | 김명숙 | - |
dc.contributor.alternativeName | 이창우 | - |
dc.contributor.alternativeName | 강종순 | - |
dc.contributor.alternativeName | 이기호 | - |
dc.contributor.alternativeName | 박성규 | - |
dc.contributor.alternativeName | 한정환 | - |
dc.contributor.alternativeName | 이희윤 | - |
dc.contributor.alternativeName | 최용석 | - |
dc.contributor.alternativeName | 권호정 | - |
dc.contributor.alternativeName | 한균희 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 22, pp. 6234-6238 | - |
dc.identifier.doi | 10.1016/j.bmcl.2007.09.034 | - |
dc.subject.keyword | Anticancer chemotherapy | - |
dc.subject.keyword | Docking model | - |
dc.subject.keyword | Enzyme inhibitor | - |
dc.subject.keyword | Growth inhibition | - |
dc.subject.keyword | HDAC | - |
dc.subject.keyword | Histone deacetylase | - |
dc.subject.keyword | In vivo xenograft model | - |
dc.subject.local | Anticancer chemotherapy | - |
dc.subject.local | Docking model | - |
dc.subject.local | Enzyme inhibitor | - |
dc.subject.local | enzyme inhibitors | - |
dc.subject.local | Growth Inhibition | - |
dc.subject.local | growth inhibition | - |
dc.subject.local | Growth inhibition | - |
dc.subject.local | HDAC | - |
dc.subject.local | Histone deacetylase | - |
dc.subject.local | histone deacetylase (HDAC) | - |
dc.subject.local | Histone deacetylases | - |
dc.subject.local | histone deacetylase | - |
dc.subject.local | In vivo xenograft model | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.